Silencing of R-Spondin1 increases radiosensitivity of glioma cells

Xuefeng Gu; Xuefeng Wang; Hong Xiao; Guoda Ma; Lili Cui; You Li; Haihong Zhou; Wandong Liang; Bin Zhao; Keshen Li

doi:10.18632/oncotarget.3395

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Silencing of R-Spondin1 increases radiosensitivity of glioma cells

Xuefeng Gu, Xuefeng Wang, Hong Xiao, Guoda Ma, Lili Cui, You Li, Haihong Zhou, Wandong Liang, Bin Zhao and Keshen Li _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:9756-9765. https://doi.org/10.18632/oncotarget.3395

Metrics: PDF 1934 views | HTML 2298 views | ?

Abstract

Xuefeng Gu1,2,*, Xuefeng Wang3,*, Hong Xiao3,*, Guoda Ma1, Lili Cui1, You Li2, Haihong Zhou4, Wandong Liang5, Bin Zhao2, Keshen Li1

1Institute of Neurology, Guangdong Medical College, Zhanjiang 524001, China

2Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China

3Department of Neurosurgery, Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China

4Department of Neurology, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China

5Renji College, Wenzhou Medical University, Wenzhou 325000, China

*These authors have contributed equally to this work

Correspondence to:

Keshen Li, e-mail: [email protected]

Bin Zhao, e-mail: [email protected]

Keywords: Rspo1, glioma, radiation

Received: December 22, 2014 Accepted: February 17, 2015 Published: March 12, 2015

ABSTRACT

Although radiation therapy is the most effective postoperative adjuvant treatment, it does not substantially improve the long-term outcomes of glioma patients because of the characteristic radioresistance of glioma. We found that R-Spondin1 (Rspo1) expression was elevated in high-grade gliomas and was associated with worse overall survival and disease-free survival. Rspo1 expression was also associated with reduced survival rates in glioma patients after treatment with radiotherapy and temozolomide (RT-TMZ). Importantly, Rspo1 was dramatically upregulated after radiation treatment in patients with glioma. Rspo1 silencing by shRNA potentiated glioma cell death upon radiation treatment. In a xenograft nude mouse model, combining radiation and silencing of Rspo1 potentiated tumor growth inhibition. Thus, combining radiotherapy with silencing of Rspo1 is a potential therapeutic approach.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3395

Publication Alerts

Research Papers:

Silencing of R-Spondin1 increases radiosensitivity of glioma cells

Abstract